Another PPAR-γ agonist pioglitazone has also been reported to decrease the M1/M2 ratio in experimental Alzheimer's disease [107], but the relationship between PPAR-γ agonists and microglia phenotype switching is still not clear. Here, PPARG is linked to Alzheimer disease.